General
Preferred name
BROMFENAC
Synonyms
AHR 10282B ()
Bronuck ()
AHR 10282R ()
Bromfenac monosodium salt sesquihydrate ()
Bromfenac sodium sesquihydrate ()
BROMFENAC SODIUM ()
Lomb-1 ()
bromfenac (low concentration), Bausch & ()
Bromfenac (sodium) ()
Bromfenac sodium hydrate ()
AHR 10282R,Bromsite,Bromday,Prolensa,Xibrom ()
Bromsite, Bromday, Prolensa, Xibrom ()
BROMDAY ()
Bromsite ()
Prolensa ()
Bromfenac monosodium salt ()
Xibrom ()
Yellox ()
AHR-10282B ()
BROMFENACO ()
ISV-303 ()
Bromfenac (sodium salt) ()
Bromfenac-d4 (sodium salt) ()
P&D ID
PD009615
CAS
120638-55-3
91714-94-2
91714-93-1
2749400-35-7
Tags
available
drug
Approved by
FDA
First approval
2005
1997
Drug indication
Inflammation
Eye inflammation
Postoperative inflammation
Ocular pain
Drug Status
approved
withdrawn
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE 29
DESCRIPTION Bromfenac sodium is a potent and orally active inhibitor of COX, with IC50s of 5.56 and 7.45 nM for COX-1 and COX-2, respectively. Bromfenac sodium can be used in ocular inflammation research[1].
DESCRIPTION Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID).
Marketed formulations may contain bromfenac sodium (PubChem CID 23693301). (GtoPdb)
PRICE 29
DESCRIPTION Bromfenac Sodium (AHR 10282R) is a nonsteroidal anti-inflammatory drug (NSAID), which has anti-inflammatory activity and may block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2. (TargetMol Bioactive Compound Library)
DESCRIPTION Bromfenac sodium hydrate (Bromfenac monosodium salt sesquihydrate) is the sodium salt form of bromfenac, a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and anti-inflammatory properties. Upon ophthalmic administration, bromfenac binds to and inhibits cyclooxygenase II (COX II), an enzyme that converts arachidonic acid to cyclic endoperoxides, which are prostaglandin (PG) precursors. By inhibiting PG formation, bromfenac prevents PG-induced inflammation, vasodilation, leukocytosis, disruption of the blood-aqueous humor barrier, increased vascular permeability, and elevated intraocular pressure (IOP). (TargetMol Bioactive Compound Library)
Compound Sets
28
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Concise Guide to Pharmacology 2025/26
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NPC Screening Collection
Other bioactive compounds
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Withdrawn 2.0
External IDs
141
Properties
(calculated by RDKit )
Molecular Weight
333.0
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
2
Rotatable Bonds
4
Ring Count
2
Aromatic Ring Count
2
cLogP
2.89
TPSA
80.39
Fraction CSP3
0.07
Chiral centers
0.0
Largest ring
6.0
QED
0.67
Structural alerts
1
anthranil_one_A(38)
c:1:c:c:c:c(:c:1-[#7&!H0;!H1,!$([#7]-[#6]=[#8])])-[#6](-[#6]:[#6])=[#8]
PAINS Family B
Custom attributes
(extracted from source data)
Target
COX
COX-1
COX-2
PTGS1, PTGS2
MOA
COX inhibitor
cyclooxygenase inhibitor
Pathway
Immunology/Inflammation
Neuroscience
ATC
S01BC11
Toxicity type
hepatic
Therapeutic Class
Antiinflammatory Agents
Source data